Inhibition of the PI3K/Akt/mTOR and ERK1/2 signaling pathways has been shown to reduce progranulin (PGRN) expression in ovarian cancer cells, suggesting a potential strategy to overcome chemoresistance in OCCC. Here, GRN is linked to ovarian carcinoma.